Shield Therapeutics (STX) Share Price, News & Analysis

Company Overview

Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.

Key Stats

• Today's Range: 2.65 to 2.72
• 50-Day Range: 2.60 to 4.92
• 52-Week Range: 1.06 to 7.80
• Volume: 1.20 million shs
• Average Volume: 4.45 million shs
• Market Capitalization: £21.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

STX Stock Analysis - Frequently Asked Questions

How have STX shares performed this year?

Shield Therapeutics' stock was trading at GBX 6.70 at the beginning of 2024. Since then, STX stock has decreased by 59.5% and is now trading at GBX 2.71.
View the best growth stocks for 2024 here.

How do I buy shares of Shield Therapeutics?

Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Shield Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), AstraZeneca (AZN), Model N (MODN), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS) and Cellectis (CLLS).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Computer Hardware
• Current Symbol: LON:STX
• CUSIP: N/A
• CIK: N/A
• Web: www.shieldtherapeutics.com
• Phone: +44-191-5118500
• Fax: N/A
• Employees: 40,000
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 38.34
• P/E Growth: N/A
• Net Income: £-36,170,000.00
• Net Margins: -168.42%
• Pretax Margin: N/A
• Return on Equity: -261.67%
• Return on Assets: -47.85%

Debt

• Debt-to-Equity Ratio: 3,691.50
• Current Ratio: 1.05
• Quick Ratio: 2.16

Sales & Book Value

• Annual Sales: £21.47 million
• Price / Sales: 0.99
• Cash Flow: GBX 0.43 per share
• Price / Cash Flow: 6.36
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 782,060,000
• Free Float: N/A
• Market Cap: £21.22 million
• Optionable: Not Optionable
• Beta: 1.42